Combination of the Immune Modulator Dimethyl Fumarate With Intraarterial Treatment in Acute Ischemic Stroke
NCT ID: NCT04891497
Last Updated: 2023-10-25
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
WITHDRAWN
PHASE2
INTERVENTIONAL
2021-06-01
2021-12-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Combination of the Immune Modulator Dimethyl Fumarate With Alteplase in Acute Ischemic Stroke
NCT04890366
An Exploratory Study of Ganglioside GM1 in Acute Ischemic Stroke
NCT04952064
Study on the Effectiveness and Safety of Shuxinin Injection in the Treatment of Acute Ischemic Stroke
NCT04950790
Methanesulfonic Acid Cinepazide Injection for Treatment of Acute Cerebral Infarction
NCT01851759
Clinical Study of Desmoteplase in Japanese Patients With Acute Ischemic Stroke
NCT01104467
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
TREATMENT
TRIPLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Intraarterial Treatment plus Dimethyl Fumarate
Dimethyl fumarate 240mg orally twice daily for 3 consecutive days
Dimethyl Fumarate
Dimethyl fumarate 240mg orally twice daily for 3 consecutive days
Intraarterial Treatment plus placebo
Placebo 240mg orally twice daily for 3 consecutive days
Placebo
Placebo 240mg orally twice daily for 3 consecutive days
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Dimethyl Fumarate
Dimethyl fumarate 240mg orally twice daily for 3 consecutive days
Placebo
Placebo 240mg orally twice daily for 3 consecutive days
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
Exclusion Criteria
2. Other diseases of the central nervous system
3. There has been a neurological disability in the past (mRS score\>2)
4. Difficulty swallowing
5. Arrhythmia, atrioventricular block
6. Use of anti-tumor drugs, other immunosuppressive and immunomodulatory drugs
7. Macular edema
8. Magnetic resonance angiography shows vertebra-basilar artery obstruction
9. Hemorrhagic stroke
10. Patients who are known to have hypersensitivity to dimethyl fumarate or any excipients of this product
11. Pregnant and lactating women
18 Years
80 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Xuanwu Hospital, Beijing
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
haojunwei5
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.